Pacira BioSciences, Inc. PCRX Fair Value Measurement Disclosure
Fair Value Measurement Disclosure at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s fair value measurement disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s fair value measurement disclosure?
- Pacira BioSciences, Inc. (PCRX) reported fair value measurement disclosure of $10.25M in Q1 2026.
- How has Pacira BioSciences, Inc.'s fair value measurement disclosure changed year-over-year?
- Pacira BioSciences, Inc.'s fair value measurement disclosure decreased by 48.8% year-over-year, from $20M to $10.25M.
- What is the long-term trend for Pacira BioSciences, Inc.'s fair value measurement disclosure?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s fair value measurement disclosure has grown at a -4.3% compound annual growth rate (CAGR), from $12.8M to $10.25M.
- What does fair value measurement disclosure mean?
- This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.